Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

JPMorgan Chase ($JPM) is pounding the table on the stock of pharmaceutical giant Eli Lilly ($LLY) as sales of its weight-loss drugs accelerate. Chr...

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Phase 1 Inflammation Study in Focus as Eli Lilly Advances New Ora...

Eli Lilly’s New Phase 1 Inflammation Drug LY5625575 Enters the Spotlight

Wall Street investment bank Raymond James Financial ($RJF) has named Ally Financial ($ALLY) to top bank stock to own now.


Ally Financial Stock (ALLY) Is Tops Among Banks, Says Raymond James

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on S&P Global (SPGI) and Ally Financial (ALLY) with bull...

Analysts Offer Insights on Financial Companies: S&P Global (SPGI) and Ally Financial (ALLY)

UBS analyst David Low maintained a Buy rating on CSL today and set a price target of A$181.00. Low covers the Healthcare sector, focusing on stocks...

UBS Sticks to Its Buy Rating for CSL (CMXHF)

RedHill Biopharma ($RDHL) divested its Talicia business to Apotex Health Corp. in an $18 million upfront plus potential milestones deal as part of ...

RedHill Sells its Talicia® H. pylori Drug Business to Apotex in $18M Deal to Fuel Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Disc Medicine (IRON), Eli Lilly & Co (LLY) and Rocke...

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Eli Lilly & Co (LLY) and Rocket Pharmaceuticals (RCKT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LL...

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

Nelly Group AB ( ($SE:NELLY) ) has shared an update. Nelly Group AB has continued its share buyback programme, repurchasing 150,000 ordinary shares...

Nelly Group Steps Up Share Buybacks to Optimise Capital Structure

Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,400.00. According to TipRanks, Field is a...

Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY)

The stock had rallied after the company’s latest earnings. 


Eli Lilly Stock (LLY) Pulls Back After Hitting Record High

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 3 study “A Phase 3, Randomized, Double-Blind Study to I...

Lilly Targets China’s Obesity Market With New Phase 3 Oral Orforglipron Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 3 RENEW-MDD-2 study from Eli Lilly And Company tests br...

Lilly’s Brenipatide Steps Into Phase 3: A New Long-Term Play in Depression Care

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study A Master Protocol for Phase 1 Clinical Trials of Multip...

Eli Lilly Expands Alzheimer’s Pipeline With New Amyloid Phase 1 Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) has launched a Phase 1 trial titled “A Pl...

Lilly Quietly Expands Its Alzheimer’s Pipeline With New Early-Stage Trial

The test has already been approved in Europe. 


Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval

Some companies view obesity medications as optional treatments. 


Eli Lilly Stock (LLY) Rattled as Companies Decline to Cover Weight-Loss Drug Costs

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has completed a Phase 1 study titled ...

Lilly’s LY4395089 Interaction Study Marks Quiet but Important Early-Stage Progress

Citadel now has a stake worth $1.1 billion. 


Eli Lilly Stock (LLY) in Focus as Hedge Fund Titan Ken Griffin Quadruples Position

An update from Nelly Group AB ( ($SE:NELLY) ) is now available. Nelly Group AB, a leading Nordic fashion e-commerce platform for young women, build...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is launching a Phase 2 study called “...

Lilly Targets COPD Growth With New Brenipatide Phase 2 Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study, officially titled “A Phase-1, Parallel-Design,...

Eli Lilly’s New Obesity Drug LY3549492 Moves Forward With Completed Phase 1 Trial

Shares in Eli Lilly ($LLY) edged higher to around $1,261 per share during Monday’s pre-market session. This followed the U.S. Food and Drug Adminis...

Eli Lilly Stock (LLY) Gains on FDA Approval for Alzheimer’s Blood Test Developed with Roche

Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,400.00. Field covers the Healthcare secto...

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Some low‑priced stocks are drawing attention from Wall Street thanks to their growth plans and strong sector trends. These names trade under $10 bu...

3 Stocks Under $10 With Over 100% Upside, According to Analysts

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) is running a Phase 3b study called ACHIEV...

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study, titled “A Study to Evaluate the Effect of Fasting Dura...

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly’s new post-approval study tracks how much mirikizumab p...

Lilly’s Mirikizumab Breast Milk Study Adds A New Layer To Immunology Safety Data

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Open-label Study to Evaluate the Ph...

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The latest update on Eli Lilly’s early-stage trial of LY4178256 s...

Eli Lilly’s New Phase 1 Study of LY4178256 Advances Its Drug Pipeline

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly And Company (LLY) has completed a Phase 3 trial called ...

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

In a report released today, Steven Wheen from Jarden upgraded CSL to a Buy, with a price target of A$207.00. Wheen covers the Healthcare sector, fo...

Positive Report for CSL (CMXHF) from Jarden

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 1 study A Phase 1, Randomized, Open-Label, Crossover St...

Eli Lilly Advances Oral Pipeline With New LY4065967 Formulation Study

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly’s latest update on study NCT06945419 shows progress on ...

Lilly’s LY4086940 Phase 1 Wrap‑Up: Reading the Signals for Obesity and Diabetes Investors

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Multicenter, Sequential-Design, Sin...

Lilly’s Lepodisiran Liver Study Completion Signals Next Steps for a Key Pipeline Asset

The drug maker is seeing accelerating sales of its weight-loss medications. 


Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Continues

Ord Minnett analyst maintained a Hold rating on CSL today and set a price target of A$152.50. In addition to Ord Minnett, CSL also received a Hold ...

Ord Minnett Sticks to Their Hold Rating for CSL (CMXHF)

In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on CSL, with a price target of A$172.00. Bailey covers the Hea...

Morgan Stanley Remains a Buy on CSL (CMXHF)

In a report released today, Thomas Wakim from Bell Potter maintained a Hold rating on CSL, with a price target of A$150.00. According to TipRanks, ...

Bell Potter Keeps Their Hold Rating on CSL (CMXHF)

Macquarie analyst maintained a Hold rating on CSL today and set a price target of A$108.00. In addition to Macquarie, CSL also received a Hold from...

Macquarie Sticks to Its Hold Rating for CSL (CMXHF)

In a report released today, David Low from UBS maintained a Buy rating on CSL, with a price target of A$158.00. According to TipRanks, Low is a 3-s...

CSL (CMXHF) Receives a Buy from UBS

In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1,400.00. Field covers the...

Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Bristol Gate Capital Partners Inc., managed by Richard Hamm, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). ...

Bristol Gate’s Richard Hamm Trims Eli Lilly Stake

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY) and Ascendis Pharma (ASND). E...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND)

Novo Nordisk ($NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly ($LLY) over what it alleges is fa...

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)

Canaccord Genuity analyst Brian McNamara maintained a Buy rating on Holley yesterday and set a price target of $7.00. The company’s shares closed y...

Canaccord Genuity Remains a Buy on Holley (HLLY)

Gamco Investors, Inc. ET AL, managed by Mario Gabelli, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

Gamco Investors’ Mario Gabelli Ups Stake in Eli Lilly

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co on August 11 and set a price target of $1,376.00. The compa...

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Vanguard ETFs are popular with investors for their broad diversification at lower costs and exposure to major parts of the market. For investors st...

3 Vanguard ETFs That Could Turn $1,000 Into Long-Term Wealth

The company continues to see strong sales of its weight-loss drugs. 


Five-Star Analyst Raises Price Target on Eli Lilly Stock (LLY) After Blowout Earnings

U.S. stocks finished a strong week with another rally on Friday after a surprisingly weak jobs report pushed investors to rethink the path for inte...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,149.36	-0.88%	2.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,149.36	-0.9%	2.22M
3
4
5
6

LLY

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel